

SCIENTIFIC REPORTS



OPEN

Exploring designability of electrostatic complementarity at an antigen-antibody interface directed by mutagenesis, biophysical analysis, and molecular dynamics simulations

Kouhei Yoshida¹, Daisuke Kuroda^{1,2}, Masato Kiyoshi³, Makoto Nakakido¹, Satoru Nagatoishi^{1,3}, Shinji Soga⁴, Hiroki Shirai⁴ & Kouhei Tsumoto^{1,2,3}

Antibodies protect organisms from a huge variety of foreign antigens. Antibody diversity originates from both genetic and structural levels. Antigen recognition relies on complementarity between antigen-antibody interfaces. Recent methodological advances in structural biology and the accompanying rapid increase of the number of crystal structures of proteins have enabled atomic-level manipulation of protein structures to effect alterations in function. In this study, we explored the designability of electrostatic complementarity at an antigen-antibody interface on the basis of a crystal structure of the complex. We designed several variants with altered charged residues at the interface and characterized the designed variants by surface plasmon resonance, circular dichroism, differential scanning calorimetry, and molecular dynamics simulations. Both successes and failures of the structure-based design are discussed. The variants that compensate electrostatic interactions can restore the interface complementarity, enabling the cognate antigen-antibody binding. Retrospectively, we also show that these mutational effects could be predicted by the simulations. Our study demonstrates the importance of charged residues on the physical properties of this antigen-antibody interaction and suggests that computational approaches can facilitate design of antibodies that recognize a weakly immunogenic antigen.

Although antigens far outnumber antibody genes, sufficient antibody diversity results from genetic and structural variation¹. During B cell development, V(D)J recombination, somatic mutations, and somatic insertions and deletions result in an antibody repertoire that can recognize the enormous number of antigens encountered over a lifetime with excellent specificity². Antibody specificity is determined by the antigen binding site called the complementarity determining region (CDR) and antigen recognition is governed by several types of interactions: hydrogen bonds, electrostatic interactions, van der Waals forces, and hydrophobic interactions³⁻⁵. As the name suggests, complementarity is a key to antigen recognition. Previous works surveyed complementarity of protein-protein interactions in terms of shape, hydrophobicity, and electrostatics⁶⁻¹¹. Among them, electrostatic interactions can be controlled by manipulating charged amino acid residues on the interaction surface. For example, generation of charge repulsion at a protein-protein interface would weaken the interaction whereas generation of charge attractions would strengthen the interaction.

¹Department of Bioengineering, School of Engineering, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan. ²Medical Device Development and Regulation Research Center, School of Engineering, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan. ³The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan. ⁴Modality Research Laboratories, Astellas Pharma Inc., 21, Miyukigaoka, Tsukuba-shi, Ibaraki, 305-8585, Japan. Correspondence and requests for materials should be addressed to K.T. (email: tsumoto@bioeng.t.u-tokyo.ac.jp)

Electrostatic force has been harnessed in antibody engineering^{12–16}. Starting from crystal structures of antigen-antibody complexes, Lippow *et al.* exploited Poisson–Boltzmann electrostatics to improve binding affinity, showing a 100-fold improvement in affinity over the wild-type antibody¹². Liu and coworkers demonstrated that substitution of multiple surface residues with charged amino acids, a technique they called supercharging, increased thermal resistance in GFP¹³. Miklos *et al.* subsequently designed thermostable antibodies based on a supercharging strategy¹⁴; they demonstrated that the designed antibodies had better thermal stability and binding affinity than the parent antibodies even though the altered positions were not in the CDRs but in the framework regions (FRs). The improved affinity was due to a faster on-rate as well as a slower off-rate as measured by surface plasmon resonance (SPR). Kiyoshi *et al.* also started with a crystal structure of an antibody–antigen complex and improved the affinity of the interaction using a computational saturation mutagenesis approach¹⁵. These researchers identified several affinity-enhancing mutations that were located at the periphery of the interface; interestingly, all were mutated to charged residues. Similarly, Fukunaga and Tsumoto improved the affinity of an anti-human cardiac troponin I antibody by substitution of multiple amino acids in FRs with charged residues¹⁶. These studies indicate that manipulating electrostatic interactions can improve physicochemical properties of antigen-antibody interactions. To achieve this approach, it is important to understand the physicochemical principles behind the electrostatic complementarity of antigen-antibody interactions.

Molecular dynamics (MD) simulations can reveal the effects of amino acid mutations on a protein structure^{17–19}. Wong *et al.* investigated how mutations rigidified CDRs utilizing MD simulations and found that simulations could be useful in designing mutations that resulted in hydrogen bonding and tight packing of side chains¹⁷. Corrada *et al.* examined correlations between structures of mutated antibodies and affinities for the antigens on the basis of computational and experimental studies, respectively, and proposed a possible mechanism of rigidification¹⁸. Clark *et al.* attempted direct calculation of relative antigen-antibody binding affinities using a free energy perturbation protocol and replica exchange solute tempering method and was able to predict the effect of alanine mutations on the relative binding affinities¹⁹. These analyses indicate that MD simulations can reveal dynamic influences that cannot be detected by analysis of a static crystal structure and can be used to predict the effects of protein manipulations on function.

In this study, to clarify the importance of electrostatic interactions and to facilitate design of antigen-antibody interactions, we investigated the effect of surface charge manipulations at an antigen-antibody interface. As a model system, we started with a crystal structure of a complex between neutralizing antibody A6 and the interferon gamma receptor (IFN γ R)²⁰ available through the Protein Data Bank (PDB)²¹. SPR measurements, circular dichroism (CD) spectra, differential scanning calorimetry (DSC), and MD simulations were performed to quantify kinetics and thermodynamics of the wild-type and the designed antigen-antibody complexes. We also attempted to predict designability of the charged residues solely using a computational approach and discuss a possible strategy to efficiently elicit antibodies against weakly immunogenic antigens by surface charge manipulations.

Results

Crystal structure of an antigen-antibody complex guides surface charge manipulations at the interface.

We chose as our model antigen-antibody system the complex of the extracellular domain D1 of IFN γ R and the antibody A6 (Fig. 1a, PDB ID: 1JRH)²⁰. Analysis of the crystal structure indicates that three electrostatic interactions contribute to stabilization of the interaction between antigen (Ag) and heavy and light chain variable domains of the antibody (V_H and V_L , respectively) (Fig. 1b). First, K52 of the antigen interacts with the charged β -carboxyl groups of D54 and D56 of the V_H domain at distances of 2.8 Å. Second, the γ -carboxyl group of E27 of the V_L domain is 3.7 Å from the guanidine group of R84 of the antigen. The main chain of R84 forms part of a β -sheet, and head of exposed side chain contributes to the electrostatic interaction. Third, the β -carboxyl group of D28 of the V_L is 4.3 Å from the antigen K98 ϵ -amino group. Both Ag:K98 and V_L :D28 are exposed to solvent and in the complex interact with each other.

We performed an SPR assay to experimentally quantify the interaction of the wild-type antibody (**Ab:WT**) with the wild-type antigen (**Ag:WT**); the affinity was high with a K_D of 87 nM (Fig. 1c and Table 1). We first investigated the importance of each charged residue on the antigen side of the interface. To abolish electrostatic interactions, we prepared three alanine mutants of the antigen, **Ag:K52A**, **Ag:R84A**, and **Ag:K98A**. The SPR measurements showed that **Ag:K52A** did not bind detectably to **Ab:WT** (Fig. 1d), suggesting that K52 of the antigen is a hot spot for the interaction with the antibody. **Ag:R84A** and **Ag:K98A** bound less tightly to the **Ab:WT** than did **Ag:WT** (K_{DS} 280 nM and 440 nM, respectively compared to 87 nM for **Ag:WT**; Fig. 1e–f, and Table 1). Compared to the wild-type antigen-antibody interaction, the off rates (k_{off}) almost unchanged, whereas the on rates (k_{on}) were slower by 3 to 4 fold for the mutant antigens, suggesting that antigen side chains R84 and K98 play important roles in the association of the antigen with the antibody, likely due to the long-range electrostatic attraction to E27 and D28 of V_L , respectively. These results indicate that mutation of a single charge-charge pair is tolerated, whereas electrostatic interactions involving more than three charged residues disrupt binding completely, perhaps because the position of each residue is cooperatively controlled by multipoint binding.

Charge complementarity recovery restores antigen-antibody binding. To explore the designability of electrostatic complementarity at the interface, we further designed three “charge-inverted” antigens (**Ag:K52D**, **Ag:R84E** and **Ag:K98D**; Fig. 2a–c). As expected, the SPR analysis of **Ag:K52D** and **Ag:R84E** showed that these charge-inverted mutants did not bind to the **Ab:WT** (Fig. 2a,b). The other variant, **Ag:K98D**, bound weakly to **Ab:WT** (Fig. 2c). These results suggested that a single electrostatic repulsion can disrupt the antigen-antibody interaction.

To determine whether compensatory changes in the antibody would restore binding, we prepared three “charge-exchanged” antigen-antibody complexes (**Ag:K52D- V_H :D54K/D56K**, **Ag:R84E- V_L :E27R**, and




Figure 1. Electrostatic interactions in the IFN γ R-A6 complex and the SPR response profiles of the wild-type and the alanine mutant complexes. **(a)** Crystal structure of the antigen (cyan) and antibody (H chain: green, L chain: magenta) complex (from PDB ID: 1JRH, only variable regions are shown). **(b)** Electrostatic interactions at the interface of the wild-type complex. Each distance of electrostatic interaction is displayed as dash lines and was measured based on the crystal structure. Antibody variable regions are numbered based on the Kabat numbering scheme. SPR response profiles of **(c) Ag:WT-Ab:WT**, **(d) Ag:K52A-Ab:WT**, **(e) Ag:R84A-Ab:WT**, and **(f) Ag:K98A-Ab:WT**. The concentrations of the antibody were 1000, 500, 250, 125, 62.5, and 31.25 nM. Raw data are in black; red lines are fitted curves. All fitted data were normalized and assume a 1:1 interaction. Binding kinetics were measured at 298 K.

Antigen-Antibody	k_{on} ($10^5 M^{-1} \cdot s^{-1}$)	k_{off} ($10^{-2} \cdot s^{-1}$)	K_D ($10^{-8} M$)
Ag:WT-Ab:WT	2.7	2.3	8.7
Ag:R84A-Ab:WT	0.74	2.1	28
Ag:K98A-Ab:WT	0.90	3.9	44
Ag:K52A-Ab:WT	N/A		
Ag:R84E-Ab:WT	N/A		
Ag:K98D-Ab:WT	N/A		
Ag:K52D-Ab:WT	N/A		
Ag:R84E-V _L :E27R	2.4	1.7	7.3
Ag:K98D-V _L :D28K	2.1	2.0	9.5
Ag:K52D-V _H :D54K/D56K	N/A		

Table 1. Kinetic parameters of SPR analyses.

Ag:K98D-V_L:D28K; Fig. 2d–f). In the antibody, the charged residues at the interface are complementary. The SPR analysis of the charge-exchanged complexes showed that **Ag:R84E** and **Ag:K98D** interacted with **V_L:E27R** and **V_L:D28K**, respectively, with binding affinities similar to the wild-type antigen-antibody interaction (K_D s 73 nM and 95 nM, respectively, versus 87 nM for **Ag:WT-Ab:WT**; Fig. 2e,f, and Table 1). Moreover, the on and off rates of the **Ag:R84E-V_L:E27R** and **Ag:K98D-V_L:D28K** complexes were similar to those of the wild-type antigen-antibody complex.

To verify that loss of binding resulting from charge inverting mutations was caused by electrostatic repulsion, we analyzed the effects of the mutations on the structure and thermostability of antigen and antibody. The CD spectra of the engineered antigens showed that the mutation of R84E changed the secondary structure of the unbound-state of the antigen (Fig. S1a). Given that R84 is partially buried inside the antigen and is part of a β -sheet structure, it was not surprising that the mutation would alter the local structure. The SPR result indicated that the corresponding mutation in the antibody, E27R in the V_L domain, restored the binding affinity to near wild-type levels. This suggests that the lack of antibody binding by **Ag:R84E** is mainly caused by electrostatic repulsion.

The individual CD spectra of the compensatory pair **Ag:K98D** and **V_L:D28K** were similar to those of the wild-type antigen and antibody (Fig. S1a,b), suggesting that these mutants did not change the conformations, and disruption/restoration of interactions between the two mutants were derived from solely change of electrostatic effect. It is worth noting that the CD spectrum of **Ag:K52D** differed from that of **Ag:WT**; this was not expected as K52 is an exposed residue (Fig. S2). In addition, the corresponding antibody **V_H:D54K/D56K** also differed in secondary structure from the wild-type antibody. This suggests that lack of binding of **Ag:K52D** to **Ab:WT** might be due not only to electrostatic repulsion but also structural distortion (Figs 2d and S1).




Figure 2. Structures and SPR response profiles of the charge-inverted and charge-exchanged mutants. (a) Ag:K52D-Ab:WT, (b) Ag:R84E-Ab:WT, (c) Ag:K98D-Ab:WT, (d) Ag:K52D-V_H:D54K/D56K (e) Ag:R84E-V_L:E27R, and (f) Ag:K98D-V_L:D28K. Structures of mutants were generated using CHARMM-GUI. The concentrations of the antibody were 1000, 500, 250, 125, 62.5, and 31.25 nM. Raw data are in black; red lines are fitted curves. All fitted data were normalized and assume a 1:1 interaction. Binding kinetics were measured at 298 K.

To further quantify the mutational effects on the structural stability, we carried out DSC assays. The DSC profiles showed that Ag:K52D had higher thermal stability than Ag:WT antigen; the $T_{m,app}$ was 4 °C higher (Fig. 3a). However, the transition peak of the mutant was broad, and a small shoulder was observed, implying that heterogeneous conformations are present. Of antibody mutants, V_H:D54K/D56K had a significantly smaller ΔH and a slightly lower $T_{m,app}$ than Ab:WT (Fig. 3b). Thus, the DSC results also imply that conformations of Ag:K52D and V_H:D54K/D56K differ from wild-type conformations and thereby disrupting the binding.

Detailed molecular characterization of mutants reveals the importance of electrostatic interactions. Next, we evaluated thermodynamics of the interactions for each mutant by SPR as a function of temperatures. The thermodynamic parameters were determined from van't Hoff plots (Fig. 4a). Although the charge-exchanged mutations were kinetically similar to wild type (Fig. 2e,f, and Table 1), Ag:R84E-V_L:E27R and Ag:K98D-V_L:D28K had different thermodynamic profiles (Fig. 4b). Compared to the wild-type antigen-antibody interaction, the Ag:R84E-V_L:E27R interaction was driven more enthalpically, whereas the balance of enthalpic and entropic contributions to the Ag:K98D-V_L:D28K interaction were almost same as those of the wild-type complex.

To understand the molecular mechanism underlying the change in thermodynamic parameters due to charge-exchanged mutations we examined the intramolecular environment surrounding each mutated charged residue. The crystal structure of the antigen-antibody complex suggests that the guanidine group of the Ag:R84 side chain has cation- π interactions with surrounding aromatic residues such as Ag:W56 and Ag:Y96. Ag:R84




Figure 3. DSC analysis of thermodynamic stabilities of antigen-antibody complexes. (a) Melting curves and calculated $T_{m,app}$ values of the antigens. Ag:WT (black), Ag:R84E (green), Ag:K98D (red), and Ag:K52D (orange). (b) Melting curves and calculated $T_{m,app}$ values of the antibodies. Ab:WT (black), V_L :E27R (green), V_L :D28K (red), and V_H :D54K/D56K (orange). The standard deviation of each $T_{m,app}$ value was calculated from the fitting curve.




Figure 4. Comparison of thermodynamic profile of antigen-antibody interactions. (a) Plots of $\ln(K_D)$ vs $1/T$ (K^{-1}) for wild-type antigen-antibody (\bullet), Ag:R84E- V_L :E27R (\blacktriangle), and Ag:K98D- V_L :D28K (\blacksquare). (b) Bar graphs of the equilibrium thermodynamic parameters obtained from van't Hoff analyses. Error bars correspond to the standard deviation. The standard deviations of ΔH and $-T\Delta S$ were calculated from the fitting data, respectively, and that of ΔG was calculated from $\Delta G = \Delta H - T\Delta S$ with error propagation. Values are reported at 298 K.

also forms an electrostatic interaction with Ag:E45 as the distance between the guanidine group of Ag:R84 and γ -carboxyl group of Ag:E45 is 2.9 Å (Fig. S2). Therefore, in addition to the salt bridge with V_L :E27 of the antibody, Ag:R84 stabilizes the structure of the antigen itself.

To further understand the molecular details of the reorganization of the electrostatic complementarity, we performed multiple 100 ns MD simulations of the wild-type complex as well as Ag:R84E- V_L :E27R and Ag:K98D- V_L :D28K complexes, which had kinetics similar to that of the wild-type complex. We first computed the root mean square deviation (RMSD) of the $C\alpha$ atoms of the complexes, except for the first and last five residues of each chain, with respect to the reference crystal structure 1JRH (Fig. S3). The RMSD values were quite stable after 20 ns. Therefore, in the analyses below, we did not consider the first 20 ns of the trajectories. First, we confirmed the stable interaction at the predicted hotspot by measurement of the distances between Ag:K52 (NZ atom) and V_H :D54 and V_H :D56 (CG atoms). In the **wild-type** complex, the distance between Ag:K52 and V_H :D54 was within 3.6 Å, which is the distance in the crystal structure, in ~100% of the snapshots in the last 80 ns of each simulation and the distance between Ag:K52 (NZ atom) and V_H :D56 (CG atom) was within 3.5 Å in $55.3 \pm 2.0\%$




Figure 5. Distances between charged residues that contribute to electrostatic interactions during the MD simulations. **(a,b)** Electrostatic interactions at the interface of the wild-type complex. Distances between each atom were displayed as dash lines. Distances between **(c)** Ag:K52 and V_H:D54, **(d)** Ag:K52 and V_H:D56, **(e)** Ag:R84 and Ag:E45, **(f)** Ag:R84 and V_L:E27, and **(g)** Ag:K98 and V_L:E27. Each distance was measured based on NZ, CG, CZ, and CD atoms of Lys, Asp, Arg, and Glu, respectively. Each 100 ns run was performed three times, indicated in red, green, and blue lines.

of the snapshots (Fig. 5a,c–d). In the crystal structure, Ag:R84 interacts with intramolecular aromatic residues (Ag:W56 and Ag:Y96) and a charged residue (Ag:E45) (Fig. S2). In two out of three simulations, Ag:R84 tended to interact with V_L:E27 as seen in the crystal structure; this interaction was observed in 77.3% and 83.3% of the snapshots, respectively. In contrast, in the other simulation Ag:R84 tended to form a salt bridge with Ag:E45; these residues were within 4.3 Å, which is the distance between CZ and CD atoms of Arg and Glu, respectively, in the crystal structure, in 48% of the snapshots, and the interaction between Ag:R84 and V_L:E27 was observed in only 26.7% (Fig. 5b,e,f). Moreover, in this simulation, V_L:E27 also interacted with Ag:K98, which was spatially adjacent to the Ag:R84. The distance between V_L:E27 (CD) and Ag:K98 (NZ) was 8.0 Å in the crystal structure, whereas the distance was less than or equal to 4.0 Å in 37.7% of the snapshots (Figs 1a and 5b,g). Thus, in the simulations of the wild-type complex, charge-charge interactions were well established during the simulations.

In the simulations of the **Ag:K98D-V_L:D28K** complex, as expected, Ag:K98D interacted with V_L:D28K within 4.0 Å in $62 \pm 2\%$ of the snapshots. In addition, Ag:K98D also interacted with Ag:R84 due to the charge attraction, and these residues were within 4.0 Å in $17 \pm 5\%$ of the snapshots. These salt bridges were mutually exclusive with the interaction network comprised of Ag:R84, Ag:E45, Ag:W56, and Ag:Y96, which was observed in the crystal structure. The Ag:K98D interaction with Ag:R84 placed Ag:R84 closer to V_L:E27 (Fig. S4a,b). In the simulations of the **Ag:R84E-V_L:E27R** complex, Ag:R84E interacted with V_L:E27R within 4.0 Å in $88 \pm 3\%$ of the snapshots. Ag:K98 attracted Ag:R84E, making a cavity near V_H:E45, V_H:Y56, and V_H:W96 (Fig. S4c,d). V_L:E27R was located in this cavity and formed interactions electrostatic or cation- π interactions with V_H:E45, V_H:Y56, and V_H:W96 (Fig. S4e). Therefore, as with the simulations of the wild-type complex, the charge-charge interactions were observed in the simulations of the two charge-exchanged complexes (**Ag:R84E-V_L:E27R** and **Ag:K98D-V_L:D28K**).

These results suggest that although the electrostatic interactions observed in the crystal structure were important in the association of mutant antigen-antibody complexes, other intermolecular and intramolecular interactions that were not obvious from the static crystal structure also play roles in the association: Surrounding residues can compensate for loss of electrostatic interactions as binding is stabilized by the surrounding residues.




Figure 6. RMSDs of the antigen-antibody interactions between simulations and initial structure. L-RMSD values of (a) wild-type antigen-antibody interactions, (b–d) charge-inverted antigen-antibody interactions, and (e–g) charge-exchanged antigen-antibody interactions. Each 100 ns run was performed three times, indicated in red, green, and blue lines. Averages and standard deviations of the L-RMSDs are indicated in parentheses.

Discussion

Electrostatic interactions are one of the important forces in antigen-antibody recognitions. Previous studies demonstrated that binding affinities of antibodies could be enhanced based on electrostatic interactions^{12,15}. Another study suggested that electrostatic interactions at antigen-antibody interfaces contributed to binding specificity and affinity due to loss of conformational flexibility through geometric constraint²². In this study, we carefully characterized the electrostatic interactions of neutralizing antibody A6 with its antigen IFN γ R as a model system for structure-based design of antigen-antibody complexes. Of three charged residues changed pair-wise, we succeeded in the modulation of electrostatic interactions for two combinations **Ag:R84E-V_L:E27R** and **Ag:K98D-V_L:D28K**. In contrast, the interactions between **Ag:K52** and **V_H:D54/D56** were not restored by the charge-exchanged mutations (Fig. 2d–f). Our biophysical analyses using CD and DSC indicate that **Ag:K52D** and **V_H:D54K/D56K** caused structural disruptions that could interfere with complex formation (Figs S1 and 3). All the three residues (**Ag:K52**, **V_H:D54/D56**) are exposed to solvent (Fig. 1b) and appeared not to form intramolecular bonds in the crystal structure. However, the **Ag:K52D** and **V_H:D54K/D56K** mutations might have affected the conformation of the antigen and the antibody, respectively. Our results demonstrate the importance of investigating structure and/or thermal stability coupled with interaction analysis when electrostatic mutation-based analyses are conducted.

Our MD simulations were able to illustrate how the charge-exchanged residues of **Ag:R84E-V_L:E27R** and **Ag:K98D-V_L:D28K** complexes modulate the electrostatic complementarity. It would be difficult to observe charge association and compensation of electrostatic interactions by surrounding residues solely from the static crystal structure and/or *in vitro* measurements. These successes provoked us to perform additional MD simulations to evaluate the predictability of effects of mutations at the antigen-antibody interface. Therefore, in addition to the aforementioned simulation studies for two charge-exchanged variants (**Ag:R84E-V_L:E27R** and **Ag:K98D-V_L:D28K**), we also conducted MD simulations of three charge-inverted variants **Ag:K52D-Ab:WT**, **Ag:R84E-Ab:WT**, and **Ag:K98D-Ab:WT** as well as the other charge-exchanged variant **Ag:K52D-V_H:D54K/D56K**. We analyzed the relative orientation between the antigen and antibody by computing RMSDs of the C α atoms of the antibody after superposing the C α atoms of the antigen in the trajectories; these values are referred to as ligand-RMSD (L-RMSD)²³. The L-RMSD of the wild-type complex was stable throughout the trajectory, suggesting that the simulation resulted in the stable conformation of the antigen-antibody complex (Fig. 6a). Our SPR assays suggested that **Ag:R84E-Ab:WT** and **Ag:K98D-Ab:WT** complexes were significantly less stable than the **Ag:WT-Ab:WT** complex (Figs 1c and 2b,c); however, the L-RMSD plots for these two complexes were similar to that for the wild-type complex (Fig. 6b,c). For the **Ag:K52D-Ab:WT** complex, L-RMSD values gradually increased, and the complex appeared to dissociate (Fig. 6d), suggesting that the simulation did appropriately reflect the weakened interaction caused by charge inversion (Fig. 2a). As expected, the L-RMSD values of two charge-exchanged variants **Ag:R84E-V_L:E27R** and **Ag:K98D-V_L:D28K** were similar to that of the wild-type complex (Fig. 6e,f) in agreement with our SPR data. Moreover, in the MD simulations, **Ag:K52D-V_H:D54K/D56K** did not form a stable complex, as reflected by high L-RMSD values during the trajectories (Fig. 6g), also concordant with our SPR analysis. From these observations, we suggested that L-RMSD from MD trajectories would be an appropriate metric that could be used to assess mutational effects on protein-protein interfaces.

Furthermore, we also performed interaction energy calculations (van der Waals plus coulomb energy) to the mutated residues in the antigen (K52, R84, and K98), enabling to complement the prediction based on L-RMSD. In the wild-type complex and the two charge-exchanged variant **Ag:R84E-V_L:E27R** and **Ag:K98D-V_L:D28K**, which were stable as shown by SPR, **Ag:K52** made the largest energy contributions, suggesting that **Ag:K52** was a hot spot in the antigen-antibody interaction, in consistent with our SPR and L-RMSD results (Fig. 7).




Figure 7. Interaction energy of the antigen-antibody interactions in the simulations. Interaction energies of antigen residues with antibody in (a) the wild-type antigen-antibody complex, (b–d) the charge inverted antigen-antibody complexes, and (e–g) charge-exchanged antigen-antibody complexes. Energies of the residues at the position of 84, 98, and 52 are shown in green, red, and orange, respectively. Standard errors were indicated by black lines (n = 3).

Importantly, the calculation showed significant loss of interaction energy due to each of the three charge-inverted mutations compared to the wild-type complex (Fig. 7a–d). Moreover, whereas the interaction energy was restored by charge-exchange mutation in **Ag:R84E-V_L:E27R** and **Ag:K98D-V_L:D28K**, the interaction energy was not restored in case of **Ag:K52D-V_H:D54K/D56K** (Fig. 7e–g). Although the calculations of interaction energies isolated only the enthalpic contribution without considering entropic effects, it showed reasonable correlation with the SPR data. Thus, MD simulations followed by energy calculations could provide important guidance for antigen-antibody manipulation, enabling computer-aided rational antibody design²⁴.

In rational antibody engineering for therapeutic and biotechnological purposes^{25,26}, antibody elicitation is the important first step. There are several methods for antibody generation but the most widely used method is animal immunization, where an antigen is injected into an animal. Certain antigens of interest are weakly immunogenic likely due to high homology to protein from immunized animal. Several display technologies have been developed to enable generation of antibodies, but acquisition of antibodies with high affinity, specificity, and stability is challenging.

As it has been suggested that only a single mutation can make proteins more immunogenic²⁷, we suggest that charge conversion is a possible strategy for generation of antibodies against weakly immunogenic antigens. First, one would modulate the surface charge of the antigen to potentiate immunogenicity. After antibodies are obtained against the charge-modulated antigen, the charged residues in the antibody that interact with modified charged residue in the antigen would be identified and converted to match that of the antibody. Our study suggests that the resultant antibody should interact specifically with original antigen (Fig. S5). In addition, our result showing that charge-inverted antibody did not bind to antigen implies that antibodies generated by immunization with charge-modified antigens will not recognize homologous proteins from host animal.

Finally, although many previous studies in protein engineering have tried to improve binding affinities by introducing electrostatic pairs, binding affinity must be modulated appropriately to retain a desired function²⁸. In this study, our designed alanine mutations resulted in the slower k_{on} but did not abolish the binding (Fig. 1e–f). The alanine mutation to a charged residue that is involved in a single negative-positive charge pairing might be a promising approach to decrease affinity by three to five fold. Thus, design of electrostatic complementarity, guided by both experiments and molecular simulations is an effective approach for manipulation of antigen-antibody interaction.

In this study, we presented the structure-based design of electrostatic complementarity of an antigen-antibody complex, and the following biophysical analysis showed the success and failure of these designed variants in terms of the recovery of binding capability. We also suggested the availability of MD-based prediction in the design of an antigen-antibody complex. Our results supplied insights that each electrostatic interaction has different role in an antigen-antibody binding process and should be considered in view of structural and dynamic aspects for rational manipulation of electrostatic complementarity.

Methods

Expression and purification of antibodies. The single-chain variable fragment (scFv) was constructed from the DNA encoding the Fab of A6; the DNA was chemically synthesized by GeneArt. A (GGGS)₃ linker was inserted between the H chain and the L chain, and the sequence was optimized for expression in *E. coli*. The A6 scFv construct was expressed in vector pRA2 to result in a hexa-histidine tag at the C terminus. The DNA sequence was confirmed by the dideoxy chain-termination sequencing method.

Cells of *E. coli* strain BL21 (DE3) (Novagen) were transformed with the A6 scFv expression vector and grown at 28 °C in LB medium. Protein expression was induced by addition of 0.5 mM isopropyl β-D-1-thiogalactopyranoside when the optical density at 600 nm reached a value of 0.6. Cells were allowed to grow for an additional 16 h at 20 °C. The cells were harvested by centrifugation at 8,000 × g for 10 min, and the pellet thus obtained was resuspended in a solution containing 0.2 M NaCl, 1 mM EDTA, and 50 mM Tris-HCl, pH 8.0 (buffer A). Cells were subsequently lysed by sonication with an ultrasonic cell-disruptor instrument (TOMY); samples were sonicated twice for 20 min each period (Output 7, Duty 50).

The pellet containing the insoluble intracellular components was obtained by centrifugation at 8,000 × g for 30 min. The supernatant was discarded, and the insoluble fraction was resuspended in 1% Triton-X100 (Wako) in buffer A. After centrifugation at 8,000 × g for 15 min, the insoluble fraction was resuspended in water, and centrifuged at 8,000 × g for 15 min; this removed the detergent. The insoluble fraction was resuspended in acetone and centrifuged at 10,000 × g for 30 min to remove lipids. The insoluble fraction was resuspended in a water to remove remaining acetone, and the inclusion body was obtained by centrifugation at 8,000 × g for 15 min. The pellet was solubilized with 6 M guanidine-HCl, 0.4 M NaCl, 20 mM Tris-HCl, pH 8.0 (buffer B) and 5 mM imidazole and incubated overnight at 4 °C. The supernatant collected after centrifugation at 40,000 × g for 30 min was applied to an Ni-NTA agarose (QIAGEN) column equilibrated with buffer B. The column was washed sequentially with 5 and 10 mM imidazole in buffer B. The A6 scFv was eluted with 300 mM imidazole in buffer B.

The purified A6 scFv was refolded using a stepwise dialysis method. The wild-type A6 scFv was diluted to 7.5 μM, and mutants were diluted to 1 μM with buffer B, followed by stepwise dialysis to remove the denaturant. In order to increase the refolding efficiency, 0.4 M Arg-HCl was added to the dialysis solution to minimize protein aggregation when the concentration of guanidine-HCl decreased from 1 M to 0.5 M as previously described²⁹. The refolded A6 scFv was concentrated and purified over an Ni-NTA agarose column, and subjected to size exclusion chromatography on a HiLoad 26/600 Superdex 75-pg column (GE Healthcare) equilibrated with 0.4 M NaCl, 1 mM EDTA, and 20 mM Tris-HCl, pH 8.0. The monomer peak fraction was collected.

Expression and purification of antigen. The DNA encoding the extracellular domain D1 of IFNγR was chemically synthesized by GeneArt with sequence optimized for expression in *E. coli*. The IFNγR construct was expressed in vector pET28b to result in a hexa-histidine tag at the C terminus. The DNA sequence was confirmed by sequencing using the dideoxy chain-termination method. Cells of *E. coli* strain BL21 (DE3) (Novagen) were transformed with the IFNγR expression vector and were grown at 37 °C in LB. Protein expression was induced by addition of 0.5 mM isopropyl β-D-1-galactopyranoside when the optical density at 600 nm reached a value of 0.6. Cells were allowed to grow for an additional 16 h at 20 °C. The cells were harvested by centrifugation at 8,000 × g for 10 min, and the pellet thus obtained was resuspended in a solution containing 0.5 M NaCl, 5 mM imidazole, and 20 mM Tris-HCl, pH 8.0 (buffer C). Cells were subsequently lysed two 20-min periods of sonication method with an ultrasonic cell-disruptor instrument (TOMY; Output 7, Duty 50).

The supernatant containing the soluble intracellular components was obtained by ultracentrifugation at 40,000 × g for 30 min. The soluble fraction was applied to an Ni-NTA agarose (QIAGEN) column equilibrated with buffer C. The column was washed sequentially with 5 and 10 mM imidazole in buffer C. IFNγR was eluted with 300 mM imidazole in buffer C. The purified IFNγR was subjected to size exclusion chromatography over a HiLoad 26/600 Superdex 75-pg column (GE Healthcare) equilibrated with 0.2 M NaCl, 1 mM EDTA, and 50 mM Tris-HCl, pH 8.0. The monomer peak fraction was collected.

Kinetic and thermodynamic SPR assays. The interaction between A6 and IFNγR was analyzed by SPR on a Biacore T200 instrument (GE Healthcare). A research-grade CM5 Biacore sensor chip (GE Healthcare) was activated by a short treatment with N-hydroxysuccinimide/N-ethyl-N'-(3-dimethylaminopropyl) carbodiimide hydrochloride, followed by immobilization of antigen IFNγR at a surface density of approximately 200 RU. The activated groups on the surface of the sensor were subsequently blocked by injecting 1 M ethanolamine as previously described³⁰. The kinetic data of the binding A6 scFv to the IFNγR were obtained by injecting increasing concentrations of A6 scFv over the sensor chip at a flow rate of 30 μl/min. The measurements were carried out in PBS containing 0.005% (v/v) Tween-20. Contact time and dissociation time were 1 min and 5 min, respectively. Data analysis was performed with the BIAevaluation software (GE Healthcare). Association (k_{on}) and dissociation (k_{off}) rate constants were calculated by a global fitting analysis assuming a Langmuir binding model and a stoichiometry of (1:1). The dissociation constant (K_D) was determined from the ratio of the rate constants as previously described³¹:

$$K_D = k_{off}/k_{on}$$

Enthalpy (ΔH) and entropy (ΔS) were calculated from the slope and intercept, respectively, of the plot of temperature versus dissociation constant using the van't Hoff approximation³²:

$$\ln K_D = \Delta H/RT - \Delta S/R$$

where R is the gas constant and T is the absolute temperature.

Circular dichroism spectra. CD spectra were recorded on a model J-820 CD spectrometer (JASCO). Far-UV CD measurements were performed with 0.5 mg/mL of IFN γ R in PBS using a 1-mm cell and a bandwidth of 1 nm. Spectra were recorded five times for each sample.

Differential scanning calorimetry. DSC measurements of samples prepared in PBS were carried out on a MicroCal VP-Capillary DSC (Malvern Instruments) at a heating rate of 60 °C per h. To evaluate thermal stability, the temperature where heat capacity was maximum was determined as apparent T_m ($T_{m,app}$) using the software MicroCal Origin 7 (Malvern).

Accessible surface area and surface charge calculations. Accessible surface area of the antigen was calculated with the Protein Interfaces, Surfaces and Assemblies (PISA) server³³. Surface charges were calculated using the protein contact potential function in PyMOL³⁴.

Molecular dynamics simulations. MD simulations of wild-type and mutant complexes were performed using GROMACS 2016.3³⁵ with the CHARMM36m force field and the CMAP correction^{36,37}. Using the CHARMM-GUI³⁸, the Fv regions of the structure of the IFN γ R-A6 complex (PDB ID: 1JRH) was solvated with TIP3P water in a rectangular box such that the minimum distance to the edge of the box was 15 Å under periodic boundary conditions. Na and Cl ions were added to neutralize the protein charge, then further ions were added to mimic a salt solution concentration of 0.14 M. Each system was energy-minimized for 5000 steps and equilibrated with NVT ensemble at 298 K for 1 ns. Further production run was performed for 100 ns with NPT ensemble. A cutoff distance of 12 Å for Coulomb and van der Waals interactions was used. Long-range electrostatics were evaluated through the Particle Mesh Ewald method³⁹. LINCS algorithm⁴⁰ was employed to constrain bonds involving hydrogen atoms. The time step was set to 2 fs throughout the simulations. A simulation was repeated 3 times for each system, and the snapshots were saved every 10 ps. PyMOL and UCSF Chimera⁴¹ were employed to analyze and visualize the MD trajectories and to render the molecular graphics. Interaction energy was defined as the sum of van der Waals and Coulomb interactions, which were calculated through GROMACS based on the last 80 ns of each trajectory.

Data Availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

- de los Rios, M., Criscitiello, M. F. & Smider, V. V. Structural and genetic diversity in antibody repertoires from diverse species. *Curr. Opin. Struct. Biol.* **33**, 27–41 (2015).
- Janeway, C. A., Travers, P., Walport, M. & Shlomchik, M. Immunobiology: The Immune System in Health and Disease. *Immuno Biol.* 5th edition, New York: Garland Science (2001).
- Reverberi, R. & Reverberi, L. Factors affecting the antigen-antibody reaction. *Blood Transfus.* **5**, 227–240 (2007).
- Akiba, H. & Tsumoto, K. Thermodynamics of antibody-antigen interaction revealed by mutation analysis of antibody variable regions. *J. Biochem.* **158**, 1–13 (2015).
- Sela-Culang, I., Kunik, V. & Ofra, Y. The structural basis of antibody-antigen recognition. *Front. Immunol.* **4**, 1–13 (2013).
- Li, Y., Zhang, X. & Cao, D. The role of shape complementarity in the protein-protein interactions. *Sci. Rep.* **3**, 3271 (2013).
- Tsuchiya, Y., Kinoshita, K. & Nakamura, H. Analyses of homo-oligomer interfaces of proteins from the complementarity of molecular surface, electrostatic potential and hydrophobicity. *Protein Eng. Des. Sel.* **19**, 421–429 (2006).
- McCoy, A. J., Chandana Epa, V. & Colman, P. M. Electrostatic complementarity at protein/protein interfaces. *J. Mol. Biol.* **268**, 570–584 (1997).
- Berchanski, A., Shapira, B. & Eisenstein, M. Hydrophobic complementarity in protein-protein docking. *Proteins Struct. Funct. Bioinforma.* **56**, 130–142 (2004).
- Lawrence, M. C. & Colman, P. M. Shape complementarity at protein/protein interfaces. *J. Mol. Biol.* **234**, 946–950 (1993).
- Kuroda, D. & Gray, J. J. Shape complementarity and hydrogen bond preferences in protein-protein interfaces: Implications for antibody modeling and protein-protein docking. *Bioinformatics* **32**, 2451–2456 (2016).
- Lippow, S. M., Wittrop, K. D. & Tidor, B. Computational design of antibody-affinity improvement beyond *in vivo* maturation. *Nat. Biotechnol.* **25**, 1171–1176 (2007).
- Lawrence, M. S., Phillips, K. J. & Liu, D. R. Supercharging proteins can impart unusual resilience. *J. Am. Chem. Soc.* **129**, 10110–2 (2007).
- Miklos, A. E. *et al.* Structure-based design of supercharged, highly thermoresistant antibodies. *Chem. Biol.* **19**, 449–455 (2012).
- Kiyoshi, M. *et al.* Affinity improvement of a therapeutic antibody by structure-based computational design: Generation of electrostatic interactions in the transition state stabilizes the antibody-antigen complex. *Plos One* **9**, e87099 (2014).
- Fukunaga, A. & Tsumoto, K. Improving the affinity of an antibody for its antigen via long-range electrostatic interactions. *Protein Eng. Des. Sel.* **26**, 773–780 (2013).
- Wong, S. E., Sellers, B. D. & Jacobson, M. P. Effects of somatic mutations on CDR loop flexibility during affinity maturation. *Proteins Struct. Funct. Bioinforma.* **79**, 821–829 (2011).
- Corrada, D. & Colombo, G. Energetic and dynamic aspects of the affinity maturation process: Characterizing improved variants from the bevacizumab antibody with molecular simulations. *J. Chem. Inf. Model.* **53**, 2937–2950 (2013).
- Clark, A. J. *et al.* Free Energy Perturbation Calculation of Relative Binding Free Energy between Broadly Neutralizing Antibodies and the gp120 Glycoprotein of HIV-1. *J. Mol. Biol.* **429**, 930–947 (2017).
- Sogabe, S. *et al.* Neutralizing epitopes on the extracellular interferon gamma receptor (IFN γ R) alpha-chain characterized by homolog scanning mutagenesis and X-ray crystal structure of the A6 fab-IFN γ R1-108 complex. *J. Mol. Biol.* **273**, 882–897 (1997).
- Berman, H., Henrick, K. & Nakamura, H. Announcing the worldwide Protein Data Bank. *Nat. Struct. Biol.* **10**, 980 (2003).
- Sinha, N., Mohan, S., Lipschultz, C. A. & Smith-Gill, S. J. Differences in electrostatic properties at antibody-antigen binding sites: Implications for specificity and cross-reactivity. *Biophys. J.* **83**, 2946–2968 (2002).
- Janin, J. *et al.* CAPRI: A critical assessment of PRedicted interactions. *Proteins Struct. Funct. Genet.* **52**, 2–9 (2003).
- Kuroda, D., Shirai, H., Jacobson, M. P. & Nakamura, H. Computer-aided antibody design. *Protein Eng. Des. Sel.* **25**, 507–521 (2012).
- Farkona, S., Diamandis, E. P. & Blasutig, I. M. Cancer immunotherapy: the beginning of the end of cancer? *BMC Med.* **14**, 73 (2016).
- Sharma, S., Byrne, H. & O’Kennedy, R. J. Antibodies and antibody-derived analytical biosensors. *Essays Biochem.* **60**, 9–18 (2016).

27. Ohkuri, T. *et al.* A Protein's Conformational Stability Is an Immunologically Dominant Factor: Evidence That Free-Energy Barriers for Protein Unfolding Limit the Immunogenicity of Foreign Proteins. *J. Immunol.* **185**, 4199–4205 (2010).
28. Yu, Y. J. *et al.* Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. *Sci. Transl. Med.* **3**, 84ra44 (2011).
29. Tsumoto, K. *et al.* Role of arginine in protein refolding, solubilization, and purification. *Biotechnol. Prog.* **20**, 1301–1308 (2004).
30. Johnsson, B., Löfås, S. & Lindquist, G. Immobilization of Proteins to a Carboxymethyl-dextran-Modified Gold Surface for Biospecific Interaction Analysis in Surface Plasmon Resonance Sensors. *Anal. Biochem.* **198**, 268–277 (1991).
31. Myszka, D. G. Kinetic analysis of macromolecular interactions using surface plasmon resonance biosensors. *Curr. Opin. Biotechnol.* **8**, 50–57 (1997).
32. Ross, P. D. & Subramanian, S. Thermodynamics of protein association reactions: forces contributing to stability. *Biochemistry* **20**, 3096–3102 (1981).
33. Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. *J. Mol. Biol.* **372**, 774–797 (2007).
34. Hagemans, D., van Belzen, I. A. E. M., Morán Luengo, T. & Rüdiger, S. G. D. A script to highlight hydrophobicity and charge on protein surfaces. *Front. Mol. Biosci.* **2**, 56 (2015).
35. Abraham, M. J. *et al.* GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. *SoftwareX* **1–2**, 19–25 (2015).
36. Huang, J. *et al.* CHARMM36m: an improved force field for folded and intrinsically disordered proteins. *Nat. Methods* **14**, 71–73 (2017).
37. MacKerell, A. D. Jr., Feig, M. & Brooks, C. L. Improved treatment of the protein backbone in empirical force fields. *J. Am. Chem. Soc.* **126**, 698–699 (2004).
38. Jo, S., Kim, T., Iyer, V. G. & Im, W. CHARMM-GUI: a web-based graphical user interface for CHARMM. *J. Comput. Chem.* **29**, 1859–1865 (2008).
39. Darden, T., York, D. & Pedersen, L. Particle mesh Ewald: An N-log(N) method for Ewald sums in large systems. *J. Chem. Phys.* **98**, 10089–10092 (1993).
40. Hess, B., Bekker, H., Berendsen, H. J. C. & Fraaije, J. G. E. M. LINCS: A Linear Constraint Solver for molecular simulations. *J. Comput. Chem.* **18**, 1463–1472 (1997).
41. Pettersen, E. F. *et al.* UCSF Chimera - A visualization system for exploratory research and analysis. *J. Comput. Chem.* **25**, 1605–1612 (2004).

Acknowledgements

The super-computing resources used in this study were provided by the Human Genome Center at the Institute of Medical Science, The University of Tokyo, Japan. This work was funded in part by Japan Society for the Promotion of Science (grant no. 16H02420 to K.T., 16H06693 to M.N., and 17K18113 to D.K.) and by Japan Agency for Medical Research and Development (grant no. JP18am0101094j, JP18dm0107064h, JP18mk0101081h, JP18fm0208030h, JP18fk0108073h, JP18ak0101100h to K.T., JP18ak0101100h to M.N. and JP18fm0208022h to D.K.).

Author Contributions

This study has been conceived by S.S., H.S. and K.T. K.Y., D.K., M.K., M.N., S.N. and K.T. designed the study. K.Y., D.K. and M.K. performed the experiments. K.Y., D.K., M.N. and S.N. analyzed the data and wrote the manuscript. All the authors approved the manuscript.

Additional Information

Supplementary information accompanies this paper at <https://doi.org/10.1038/s41598-019-40461-5>.

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019